XNYS · Drug Manufacturers - General
Last stored close · Nov 10, 2026
Close · Nov 10, 2026
$280.78-0.47%
Model Target
available with Pro
Implied upside
vs the model target
Valuation methods
the methods behind the target
TickerWhale Score
63/100
Positive
Score components
TickerWhale View
Johnson & Johnson scores 63 out of 100 overall, which we rate positive. Technical is its strongest area and Valuation its weakest.
What helps
- Technical
- Quality & growth
- Risk
What to watch
- Valuation
- Sentiment Signal
Quality & growth
30%54Moderate
- Revenue growth 8.1%
- EPS growth -7.8%
Valuation
25%42Weak
- P/E 32.6
- EV/Sales 7.3
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
#18 by market cap in our coverage · ~140,800 employees · Listed 1944-09-25 · www.jnj.com
Price history
Intraday to five-year windows are free with an account
Members switch between 1D, 1M, 6M, 1Y, 2Y and 5Y and see the live price. Signed out, this is the one-year stored series the technicals below are computed from.
Market intelligence
Peer position
#32 / 139sector rank by TickerWhale Score
TickerWhale Score 63 vs sector average 54.6 (+8.4)
Revenue growth (industry)Top 45%
Gross margin (industry)Top 91%
Return on equity (industry)Top 40%
P/E (industry)Cheaper than 60%
Technical analysis
our read · what classic indicators sayTickerWhale technical read
94/100Strong vs universe
Ranks 94th of 100 covered names on our technical composite — the composite itself scores 83/100 · 25% of the TickerWhale Score
Classic chart indicators
Buy
5 buy · 2 sell · 1 neutral of 8 votes
TickerWhale rates JNJ's technical setup strong — 94th percentile of the covered universe. Classic chart indicators lean buy, pointing the same way.
Moving averages
9 / 9constructive
- vs 200-day+12.8%
- vs 50-day+5.4%
Momentum
Mixed
- RSI (14)62 · neutral
- Stochasticsell
- CCIbuy
- Williams %Rsell
Trend
Constructive
- ADX (14) trend strength28· trending
- MACD (12,26,9)buy(histogram 1.649)
How the classic verdict is reached
Moving averages (9) agree on buy — 9 buy vs 0 sell — and carry one vote between them.
Oscillators (7) vote individually: 4 buy · 2 sell · 1 neutral.
Result — 5 buy vs 2 sell of 8 votes = Buy. Neutral votes never decide the verdict.
Fundamentals & valuation
2026-11-10 · revised_latestValuation multiples
- P/E (TTM)32.6
- P/S (TTM)7.0
- P/B8.1
- EV/EBITDA—
- EV/Sales7.3
- PEG—
Profitability & returns
- Gross margin67.9%
- Net margin21.5%
- ROE25.3%
- Debt/Equity0.58
Growth
- Revenue growth (YoY)8.1%
- EPS growth (YoY)-7.8%
Green favourable · red stretched — multiples and D/E vs industry peers, margins and growth vs absolute thresholds.
Market capitalisation — $685.1B
Fundamentals history
Reported statement totals across recent periods.
| Metric | Dec '25 | Dec '24 | Dec '23 |
|---|---|---|---|
| Revenue | $94.2B | $88.8B | $85.2B |
| Gross profit | $63.9B | $61.4B | $58.6B |
| Operating income | $25.3B | $20.8B | $21.2B |
| Net income | $26.8B | $14.1B | $35.2B |
| EPS (diluted) | $11.03 | $5.79 | $13.72 |
| Free cash flow | $19.7B | $19.8B | $18.2B |
| Cash | $19.7B | $24.1B | $21.9B |
| Total debt | $47.9B | $36.6B | $29.3B |
| Equity | $81.5B | $71.5B | $68.8B |
| Net debt | $28.2B | $12.5B | $7.5B |
| Debt / equity | 0.59 | 0.51 | 0.43 |
| Liabilities / assets | 0.59 | 0.60 | 0.59 |
Fundamentals are stored revised/latest (ADR-009): each period reflects the most recent vendor refresh, NOT point-in-time as-reported values. Do not use this series to claim what was known on a past date.
Model Target
Model Target is a Pro feature
Scores, factors and technicals stay free. The model's price target is part of TickerWhale Pro.
The Model Target is a TickerWhale Pro feature
A target exists for this name — the model priced it in the latest nightly run. Pro members see the target, its range and the methods behind it; one name's target is free every trading day.
Or see the current free one: KNSA →
Peers
| Company | Score | Pulse | P/E | P/E fwd | P/B | EV/Sales | Price | Chg | Estimate | Upside | Rev. gr. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| JNJCurrentJohnson & Johnson | 63 | 83 | 32.6 | — | 8.1 | 7.3 | $280.78 | -0.47% | +8.1% | ||
| EXELExelixis | 82 | 88 | 21.3 | — | 9.9 | 7.4 | $70.58 | -1.62% | +9.2% | ||
| KNSAKiniksa Pharmaceuticals International plc. - | 79 | 81 | 98.2 | — | 12.1 | 9.3 | $95.02 | -3.79% | +58.9% | ||
| THCTenet Healthcare | 79 | 81 | 10.9 | — | 5.2 | 1.6 | $290.27 | +0.44% | +7.5% | ||
| INCYIncyte | 76 | 67 | 15.5 | — | 3.9 | 3.6 | $120.30 | -1.30% | +26.9% | ||
| LIVNLivaNova | 76 | 84 | 27.2 | — | 3.9 | 3.3 | $91.14 | -1.59% | +12.4% |
News, sentiment, the Street view and Ask Willy are free with an account
A free account shows the stories attached to this name, the Sentiment Signal breakdown, analyst consensus, the options read and the AI narration of the model output.